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between February and May 2005 in a cross-sectional, obser-
vational study. RESULTS: Fourteen global and 57 detailed 
concepts were included in the conceptual model. The test ques-
tionnaire contained 64 items. After cognitive debrieﬁng, 7 items
were excluded. The questionnaire was well-accepted by the
patients in the pilot study. Clinicians were delighted to have a
helpful patient-management tool. The pilot questionnaire con-
tained 52 items in 10 sections (symptoms, allergy in daily life,
motivations for SIT, advantages, constraints, intake, outcomes,
satisfaction, intention, information). The majority of the 211
clinicians reported high patient acceptability and major interest
in using the questionnaire routinely. The items presenting missing
data, not clearly related to a speciﬁc domain, or redundant were
not selected for ﬁnal format and score calculation. The scores
were assessed for internal consistency reliability, construct valid-
ity and predictive validity. CONCLUSION: This instrument
covers the major domains impacting the patient’s persistence in
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OBJECTIVE: To assess the balance between costs and upper 
GI side effects of treatment with celecoxib (a COX-2 speciﬁc
inhibitor) compared with nonspeciﬁc NSAIDs alone, nonspeciﬁc
NSAIDs plus misoprostol, nonspeciﬁc NSAIDs plus histamine-2
receptor antagonists (H2RA), nonspeciﬁc NSAIDs plus proton
pump inhibitors (PPI), and Arthrotec, in The Netherlands.
METHODS: A model was used to convene data from various
sources. The probabilities of GI side effects for celecoxib and
nonspeciﬁc NSAIDs alone were derived from trial data, while 
all other probabilities were derived from published sources.
Resource use was derived from databases and an expert panel.
Calculations were based on 6 months of treatment, and were
from a societal perspective but were limited to direct medical
costs (2004 Euros; €). Distinction was made between risk groups
based on risk factors such as older age, use of corticosteroids
and history of GI events. RESULTS: Treatment with celecoxib
was associated with the lowest number of GI side effects and
related deaths. Assuming an average patient, the total costs per
6 months of therapy were: celecoxib €212, nonspeciﬁc NSAIDs
alone €151, NSAIDs plus misoprostol €227, NSAIDs plus
H2RAs €268, NSAIDs plus PPIs €269, and Arthrotec €171.
Incremental costs per life-year saved for celecoxib compared
with nonspeciﬁc NSAIDs alone were €12,417 for all patients,
and -€760 for high-risk patients. Comparing celecoxib and
Arthrotec, the incremental costs per life-year saved were €32,757
for all patients and €7759 for those at high-risk of GI events.
CONCLUSION: Celecoxib is a more effective and less costly
treatment than nonspeciﬁc NSAIDs plus misoprostol, NSAIDs
plus H2RAs, and NSAIDs plus PPIs. It is cost-effective compared
with nonspeciﬁc NSAIDs alone for patients at medium- to high-
risk of GI events, and also for high-risk patients. Compared with
Arthrotec, celecoxib showed an improving cost-effectiveness
proﬁle with increasing GI risk.
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OBJECTIVES: Total Hip Replacement (THR) is regarded as gold
standard treatment for degenerative hip disease in elderly
patients. Young, active patients, however, are a more challeng-
ing group for THR due to the high risk of revision and associ-
ated complications. In 2002, the National Institute for Health
and Clinical Excellence (NICE) recommended MoM hip resur-
facing as a treatment option for this patient group. An alterna-
tive treatment for these patients is watchful waiting (WW)
whereby patients are maintained on drug-based regimens until
they are old enough to warrant a THR. The aim of this study
was to evaluate the cost-effectiveness of BHR vs. WW in 45–55
year old patients with severe hip damage. For completeness the
cost-effectiveness of BHR vs. THR was assessed in the same
patient group. METHODS: A health economic model was con-
structed to assess the efﬁcacy, cost and health-related quality of
life associated with BHR, WW and THR treatments. Efﬁcacy
data for BHR were obtained from a large, prospective database
(n = 4424), which provided up to 5 years follow-up for individ-
ual BHR patients. Resource use and utility data were obtained
from published sources. The primary outcome from the model
was the cost per quality-adjusted life-year (QALY). RESULTS:
Preliminary results demonstrate that at year 5 BHR has an incre-
mental cost/QALY (ICER) of £1,101 compared to WW and an
ICER of £13,125 compared to THR. Over time the ICER
decreases and BHR becomes dominant (i.e. it is more effective
and costs less) compared to WW and THR by year 20 and 15,
respectively. CONCLUSIONS: This study demonstrates that in
patients aged 45–55 years with severe hip damage, BHR offers
an extremely cost-effective alternative to WW with an equiva-
lent improvement in quality of life to THR. Patients treated with
BHR will beneﬁt from signiﬁcant health gains at an acceptable
cost.
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OBJECTIVES: OA is associated with signiﬁcant disability,
reduced productivity, decreased HRQoL, and increased health
care costs. The objective was to evaluate the cost-effectiveness of
controlled-release oxycodone (CRO) from a societal perspective
incorporating time loss (paid and unpaid work for patients and
friends/relatives). METHODS: Open-label, active-controlled,
randomized, naturalistic 4-month study of effectiveness and 
cost-effectiveness of CRO vs. short-acting opioids. Outcomes,
resource utilization and time loss were collected by telephone.
Quality-adjusted-life-years (QALYs) were calculated from HUI3
scores. Cost-effectiveness was measured as cost/QALYs gained
and cost/patient improved. RESULTS: Patients treated with
CRO compared to short-acting opioids were more productive
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over 4-months [mean productivity gain in favor of CRO: US$11
paid work; US$654 unpaid work]. Friends/relatives of patients
on CRO also spent less time assisting patients [mean productiv-
ity gain over 4-months in favor of CRO: US$21 paid work;
US$185 unpaid work]. Improved pain control was observed in
patients treated with CRO compared to short-acting opioids as
measured by a) proportion of patients with at least a 20%
improvement in WOMAC pain score 62.2% vs. 45.9% (p =
0.0003), b) mean HUI3 utility pain domain score at 4-months
(0.53 vs. 0.46), and c) a mean QALY gain of 0.0105 with CRO
(p = 0.1673). Mean societal cost/patient over 4 months was
US$6792 vs. US$6929 (p = 0.3345) for CRO and short-acting
opioids, respectively. CRO was both more effective and less
costly than the short-acting opioids. CONCLUSIONS: CRO
offers advantages over short-acting opioids in terms of reduced
time loss from paid and unpaid work. From the societal per-
spective, CRO was both more effective (QALYs,utilities gained
and % patients improved) and less costly than short-acting
opioid. These ﬁndings, including the impact of productivity loss
and QALYs gained should be factored into decisions about treat-
ing OA pain.
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OBJECTIVE: To demonstrate that the long term use of chon-
droitin sulfate (CS) for patients suffering osteoarthiritis (OA) is
cost-saving. METHOD: Two groups were compared, patients
treated less than 6 consecutive months (short term) with CS and
patients treated more than 6 consecutive months with CS during
2001–2002 on the IMS Disease Analyzer database. The mean
cost per patient and per month was calculated using the total
cost of treatment of the period divided by the number of patients
and the mean duration of the period (12 months for the follow
up, less or more than 6 months in the treatment period). All the
analyses were performed within a French NHS perspective.
RESULTS: We obtained two groups of respectively 56,525 and
24,732 patients treated with CS for their OA in the short and
long term groups. In the follow up period, 12 months in each
group; the mean monthly cost per patient was €9.10 for the short
term group, versus €8.18 for the long term group. This saving
of almost €11.1 per year and per patient could induce an impor-
tant saving of € 627,427.5 for the French NHS if all treated with
CS on a short term were treated on a long term. In the follow
up treatment period, patients with short term treatment cost
patients with short term treatment cost 36% more in coxibs and
42% more in NSAIDs and 190% more in analgesics (p < 0.05).
CONCLUSION: The use of CS in OA is more efﬁcient with long
term treatment, demonstrating an important cost-saving versus
short term treatment. Our economical evaluation conﬁrmed the
previous clinical demonstration of the relevance of long term use
of CS in OA.
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OBJECTIVE: To demonstrate that the long term use of chon-
droitin sulfate (CS) for patients suffering osteoarthiritis (OA)
induced less co-prescriptions. METHOD: Two groups were com-
pared, patients treated less than 6 consecutive months (short
term) with CS and patients treated more than 6 consecutive
months (long term) with CS during 2001–2002 on the IMS
Disease Analyzer database. The objective was to compare the co-
prescriptions related to OA for both groups of patient in the 12
months following the study period. In our analysis, medical con-
sultations for OA and OA prescriptions including CS, NSAIDs,
analgesics, coxibs and gastro-protective agents were taken into
account. RESULTS: We obtained two groups of respectively
56,525 and 24,732 patients treated with CS for their OA in the
short and long term groups. In the follow up period, patients
with short term and long term treatment had respectively in term
of co-prescriptions 37% vs. 38% of NSAIDs, 75% vs. 71% of
analgesics and 21% in both groups of coxibs. But the mean
length of treatment’s days by co-prescriptions were respectively
of 40 vs. 37 for NSAIDs, 82 vs. 68 for analgesics and 79 vs. 59
for coxibs (p < 0.01). CONCLUSION: The results of this survey
allowed us to conclude that in addition to the fact that the use
of CS in OA is more efﬁcient with long term treatment, it was
also safer compared to short term treatment. A long term treat-
ment reduces the length of treatment of each co-prescriptions.
The saving of 20 days of coxibs treatments, 3 days of NSAIDs
and 14 days of analgesics demonstrated that the long term use
of CS conﬁrmed that in real life the efﬁciency and the safety
proﬁle made it a safe approach taking into consideration the high
risk proﬁle (Gastro-intestinal, cardiovascular, etc.) of the other
OA symptomatic treatments.
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OBJECTIVE: To evaluate upper GI (UGI) events, use of GI med-
ications, and health care costs among arthritis patients in a
managed care setting. METHODS: Commercial claims data for
three million health maintenance (HMO) and preferred provider
organization (PPO) members in Southeast U.S. were used to
identify new users of COX-2s and NSAIDs in 2002. Patients had
≥1 arthritis-related claim followed by an index claim for COX-
2 (rofecoxib, valdecoxib or celecoxib) or NSAID (ibuprofen,
naproxen, diclofenac, and nabumetone) and were continuously
enrolled for ≥ one year pre- and post-index date. Patients dis-
pensed either a COX-2 or NSAID during one year pre-index and
patients with claims for both COX-2s and NSAIDs were
excluded. Multiple logistic regression was used to model UGI
events (ulcers and bleeds) and GI medication use (proton pump
inhibitors and H2-antagonists), and a log transform model was
used for total health care costs (medical and prescription) at 1
year controlling for age, gender, health status, medication per-
sistence, and baseline utilization. RESULTS: In total, 3449
arthritis patients were included: 47% COX-2 (26% rofecoxib,
15% celecoxib, 7% valdecoxib) and 53% NSAID. Patients in
the COX-2 group were signiﬁcantly older, taking more medica-
tions and more persistent, more likely to be female or belong to
a PPO, and had more comorbidities, GI events, and higher costs
